365 Days of Progress In Breast Cancer

16.1K

views

45

authors

7

articles

365 Days of Progress In Breast Cancer

16.1K

views

45

authors

7

articles

Editors

2

Peter MacCallum Cancer Centre

Paula R Pohlmann

University of Texas MD Anderson Cancer Center

Impact

About

“365 Days of Progress” is part of a wider series of Research Topics across Frontiers in Oncology, hosted by our Specialty Chief Editors, showcasing popular articles from 2021 igniting interest in the field.

This Research Topic aims to highlight the work featured and spark further discussion. The Breast Cancer field is continuously evolving, therefore we are seeking to understand developments and perspectives on articles that have attracted attention throughout the year.

We welcome Opinions, Perspectives, and Mini-Review article types to facilitate this discussion. We also welcome updated original data following the research featured in this collection. Please note only papers that are relevant and add a significant contribution to the discussion articles will be considered.

The chosen manuscripts are :

- Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

- Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer

- The Global, Regional, and National Burden and Trends of Breast Cancer From 1990 to 2019: Results From the Global Burden of Disease Study 2019

- Obese Adipose Tissue as a Driver of Breast Cancer Growth and Development: Update and Emerging Evidence

- Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status

- Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer

- Advancements in 3D Cell Culture Systems for Personalizing Anti-Cancer Therapies

- A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo

Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

“365 Days of Progress” is part of a wider series of Research Topics across Frontiers in Oncology, hosted by our Specialty Chief Editors, showcasing popular articles from 2021 igniting interest in the field.

This Research Topic aims to highlight the work featured and spark further discussion. The Breast Cancer field is continuously evolving, therefore we are seeking to understand developments and perspectives on articles that have attracted attention throughout the year.

We welcome Opinions, Perspectives, and Mini-Review article types to facilitate this discussion. We also welcome updated original data following the research featured in this collection. Please note only papers that are relevant and add a significant contribution to the discussion articles will be considered.

The chosen manuscripts are :

- Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

- Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer

- The Global, Regional, and National Burden and Trends of Breast Cancer From 1990 to 2019: Results From the Global Burden of Disease Study 2019

- Obese Adipose Tissue as a Driver of Breast Cancer Growth and Development: Update and Emerging Evidence

- Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status

- Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer

- Advancements in 3D Cell Culture Systems for Personalizing Anti-Cancer Therapies

- A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo

Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

Share

Editors

Peter MacCallum Cancer Centre

Paula R Pohlmann

University of Texas MD Anderson Cancer Center

Impact

16,098 Total views

11,717 Article views

3,935 Article downloads

446 Topic views

Published In

Journal Thumbnail

Frontiers in Oncology

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic